Centessa Pharmaceuticals PLC

Latest Results (10.10.2025):

Centessa Pharmaceuticals PLC reported its financial results for the fourth quarter and full year ended December 31, 2024. The company maintained a strong cash position, continued to invest in research and development, and reported a net loss attributable to ordinary shareholders for both the quarter and the full year.

Cash Position

As of December 31, 2024, Centessa Pharmaceuticals held $482.2 million in cash, cash equivalents, and short-term investments. This financial position is expected to fund operations into mid-2027, providing the company with a solid runway for its ongoing and planned initiatives.

Research & Development Expenses

R&D expenses increased to $60.9 million for the fourth quarter of 2024, up from $29.7 million in the same quarter of 2023. For the full year, R&D expenses were $150.2 million compared to $124.4 million in 2023. The rise in expenses included a one-time charge of $31.5 million related to the discontinuation of the global clinical development program for SerpinPC.

General & Administrative Expenses

General and administrative expenses rose slightly to $13.7 million for the fourth quarter of 2024 from $12.3 million in Q4 2023. For the full year, these expenses decreased to $50.8 million compared to $53.7 million in 2023, reflecting effective cost management in administrative functions.

Net Loss

The net loss attributable to ordinary shareholders was $111.3 million for Q4 2024, significantly higher than the $36.8 million loss in Q4 2023. For the full year, the net loss was $235.8 million, up from $151.1 million in 2023. This increase in net loss includes non-recurring items such as a $34.1 million loss on debt extinguishment and the aforementioned $31.5 million charge related to SerpinPC.